These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2932213)

  • 1. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
    Izuo M; Yoshida M; Tominaga T; Abe O; Enomoto K; Nomura Y; Kubo K; Takatani O
    Cancer; 1985 Dec; 56(11):2576-9. PubMed ID: 2932213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
    Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D
    J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).
    Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Mazy V
    Acta Oncol; 1989; 28(2):237-40. PubMed ID: 2525397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients.
    Martoni A; Longhi A; Canova N; Pannuti F
    Oncology; 1991; 48(1):1-6. PubMed ID: 1824798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
    Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
    Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).
    Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Salamon E
    Anticancer Res; 1986; 6(5):1095-9. PubMed ID: 2948442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
    Jakobsen A; Frederiksen PL; Møller KA; Andersen AP; Brincker H; Dombernowsky P; Hansen PV; Hesselius I; Kjaer M
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1067-72. PubMed ID: 2946583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.
    Gallagher CJ; Cairnduff F; Smith IE
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1895-900. PubMed ID: 2963746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
    Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.